Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Rytelo

(ry-TEL-oh)
A drug used to treat low-risk or intermediate-1 risk myelodysplastic syndromes in adults with anemia. It is used in patients who need regular red blood cell transfusions and did not respond to or cannot be treated with an erythropoiesis-stimulating agent. It is also being studied in the treatment of other types of cancer. Rytelo binds to an enzyme called telomerase, which is found at high levels in certain types of cells, including cancer cells. Blocking the activity of this enzyme may help keep cancer cells from growing and dividing and cause them to die. Rytelo is a type of enzyme inhibitor. Also called imetelstat sodium.
More Information
Search NCI's Dictionary of Cancer Terms